磁共振成像与磁共振腔内活检在前列腺癌主动监测中的II期前瞻性盲法试验
这项前瞻性单臂非随机研究纳入82例低危前列腺癌男性,平行比较两种活检策略:对mpMRI可疑者行磁共振腔内联合经直肠超声活检,以及对全部82例盲法行经直肠超声活检。结果显示两种策略对临床有意义前列腺癌的检出率均为80%,但前者仅需27例接受活检。
要点
- mpMRI可疑者27例中检出8例临床有意义前列腺癌。
- mpMRI不可疑的55例仅行经直肠超声活检,检出2例临床有意义前列腺癌。
- 两种策略检出率均为80%,但联合活检策略仅需27例活检。
核心结论
- 对mpMRI可疑者联合经直肠超声与磁共振腔内活检,临床有意义前列腺癌检出率与全部行经直肠超声活检相似,但仅需三分之一男性接受活检。
- 结果表明磁共振腔内活检与经直肠超声活检继续互补。
研究设计与样本
- 前瞻性、单臂、非随机研究,纳入82例低危前列腺癌男性。
- 平行比较两种活检策略:对mpMRI可疑者行磁共振腔内联合经直肠超声活检;对全部82例盲法行经直肠超声活检。
主要发现
- 82例中27例mpMRI可疑,其中8例活检检出临床有意义前列腺癌,2例仅磁共振腔内活检检出,3例仅经直肠超声活检检出,3例两种活检均检出。
- 82例中55例mpMRI不可疑,仅接受经直肠超声活检,其中2例检出临床有意义前列腺癌。
- 全部82例行经直肠超声活检可正确诊断80%的临床有意义前列腺癌男性,需全部82例接受活检(82例活检中临床有意义前列腺癌占10%)。
- 对mpMRI可疑者行磁共振腔内联合经直肠超声活检也可检出80%的临床有意义前列腺癌男性,仅需27例接受活检(27例活检中临床有意义前列腺癌占30%)。
临床怎么用
- 对mpMRI可疑者联合行磁共振腔内与经直肠超声活检,仅需三分之一男性接受活检即可达到与全部行经直肠超声活检相似的临床有意义前列腺癌检出率。
- 作者认为磁共振腔内活检与经直肠超声活检继续互补。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To demonstrate the added benefit of multiparametric (mp)MRI risk stratification during active surveillance. METHODS: This prospective, single-arm, nonrandomized study included 82 men with low-risk prostate cancer (PCa). We compared two biopsy strategies in parallel. The first biopsy strategy was an in-bore and transrectal ultrasound (TRUS) biopsy in men with suspicious mpMRI findings. The second was a TRUS biopsy in all 82 men, blinded to the results of the previously performed mpMRI. RESULTS: We identified 27/82 men with suspicious mpMRI. Of those 27 men, we detected 8/27 with csPCa on biopsy, and we identified two men with in-bore biopsy exclusively, three men with TRUS biopsy exclusively, and three men with both biopsy strategies. Of the 55/82 men with nonsuspicious mpMRI (who only received TRUS biopsies), two men had csPCa. TRUS biopsy of the entire cohort of 82 men would have led to the correct diagnosis of 80% men with csPCa, requiring all 82 men to receive biopsies (csPCa in 10% of the 82 biopsies). Conducting in-bore biopsies plus TRUS biopsies in men with suspicious mpMRI would have also led to the detection of 80% of men with csPCa, requiring only 27 men to receive biopsies (csPCa in 30% of the 27 biopsies). CONCLUSION: The combination of TRUS and in-bore biopsies, limited to men with suspicious mpMRI, resulted in a similar detection rate of csPCa compared to TRUS biopsies of all men but required only one-third of men to undergo biopsy. Our results indicate that in-bore and TRUS biopsies continue to complement each other.
引用
- Langbein BJ, Berk B, Bay C, et al. A Phase II Prospective Blinded Trial of Magnetic Resonance Imaging and In-Bore Biopsy in Active Surveillance for Prostate Cancer. Urology. 2024. PMID: 38218388. doi:10.1016/j.urology.2023.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。